The MTCH2 Knockout Raji Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphocyte line, offering a loss-of-function model for mitochondrial carrier homolog 2 (MTCH2). This polyclonal pool, generated through CRISPR/Cas9-mediated gene disruption, provides a heterogeneous mixture of cells with targeted MTCH2 modifications, suitable for investigating gene function without the need for clonal isolation. The population reflects a varied knockout landscape, enabling studies that account for genetic heterogeneity.
Raji cells are an Epstein-Barr virus (EBV)-positive Burkitt’s lymphoma-derived B lymphocyte cell line that grows in suspension and is widely used to model B-cell malignancies, antigen presentation, and humoral immunity. As a transformed B-cell line, Raji cells retain key features of B lymphocytes, including surface immunoglobulin expression and major histocompatibility complex (MHC) molecules, making them valuable for immunological and cancer biology studies. The EBV status also contributes to their proliferative capacity and resistance to apoptosis, providing a relevant backdrop for investigating mitochondrial apoptotic pathways in lymphoma.
MTCH2 is a mitochondrial outer membrane receptor for truncated Bid (tBid), critically facilitating tBid-induced mitochondrial outer membrane permeabilization (MOMP), cytochrome c release, and subsequent caspase-9/-3 activation in the intrinsic apoptotic pathway. MTCH2 also participates in mitochondrial dynamics and lipid metabolism, interacting with BAX, BAK, and mitofusin 2. Its function is regulated by death receptor ligands (FasL, TRAIL), caspase-8-mediated Bid cleavage, and p53-dependent DNA damage signals, which converge on tBid generation. Downstream of MTCH2, MOMP leads to apoptosome formation, while MTCH2 also modulates DRP1 and OPA1 activities, linking apoptosis to mitochondrial morphology.
In Raji Burkitt’s lymphoma cells, MTCH2 disruption provides a model to dissect mitochondrial apoptosis in B-cell malignancy, where evasion of intrinsic apoptosis contributes to lymphomagenesis and drug resistance. MTCH2??s role as a tBid receptor positions it at a convergence point for death receptor and mitochondrial pathways, making this knockout population valuable for studying chemosensitivity and heterogeneous tumor responses. This polyclonal system reflects the genetic diversity of tumors, enabling identification of MTCH2-dependent vulnerabilities relevant to non-Hodgkin lymphomas.
Key applications include apoptosis resistance studies, mitochondrial function assays (cytochrome c release, JC-1 staining), caspase activity measurements, and chemotherapeutic sensitivity screens. The cells are suitable for Western blotting, RT-qPCR confirmation, and proliferation assays. This knockout model is particularly useful for exploring MTCH2-dependent mechanisms in B-cell malignancies, metabolic syndrome, and obesity-associated cancers. For further information, please contact Ascent Research.
